NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom.

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.

Nutri Co., Ltd. develops, manufactures, and distributes food products for disease treatment. Its products include V CRESC, V CRESC CP 10, V CRESC Jelly, V CRESC Hi-Petit Jelly, Softia, Isotonic jelly and ISOFO jelly. The company was founded in 1963 and is headquartered in Yokkaichi, Japan.

Part of Kitasato University, The Kitasato Institute is a company headquartered in Tokyo, Japan, that operates a research institution.

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options.

Innovative Biosensors' technology is built upon a foundation of a genetically engineered biosensor that allows for extremely rapid testing of analytes, providing high levels of sensitivity and specificity. The patented, self-contained biosensor system is capable of generating a sensitive and specific result with minimal amount of reagents in minutes, making it a cost-effective alternative to traditional laboratory testing. In addition, the biosensors can be engineered to detect one target or several targets of interest simultaneously and used to perform a wide variety of bioassays. Designed for real-time detection, minimally-skilled personnel can perform tests and analysis at the site of sampling using small, portable, space-saving instrumentation

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.

APIRX Pharmaceuticals USA LLC, part of Incannex Healthcare Ltd., is a company headquartered in the United States that provides research, development, and production of prescription pharmaceutical cannabinoid medicines. It was founded by Lekhram Changoer and George E. Anastassov. Incannex Healthcare Ltd. acquired APIRX Pharmaceuticals USA LLC on August 04, 2022 for $30.91 million.

Meiji Seika Pharma Co., Ltd. engages in the business of manufacture and distribution of pharmaceutical products. It also engages in the animal health business. The company was founded on October 9, 1916 and is headquartered in Tokyo, Japan.

Lintec Corp. develops, manufactures, and sells pressure-sensitive adhesive materials in Japan and internationally.

Olymvax is a biopharmaceutical firm that develops, manufactures, and sells human vaccinations. They are integrating global resources, maintaining cooperation with all parties, and striving to develop technological innovation for the development of vaccines. Their products include the tetanus vaccine and the Haemophilus influenzae B vaccine.

GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. Using a proprietary platform, GangaGen is developing highly-specific therapeutic proteins called ectolysins to target clinically meaningful types of bacteria. The company’s lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA).

Synedgen is a bio-pharmaceutical company committed to developing novel therapies and products that reduce infection and inflammation at dermal, oral, mucosal, and ophthalmic surfaces. It uses a comprehensive approach using novel polysaccharide derivatives that minimize or treat infections by targeting sites where bacteria enter the human body and encourage healing after infection or acute and chronic damage. Synedgen was formed in 2009 through the merger of BioSTAR West (Claremont, California) and Hawaii Chitopure (Honolulu, Hawaii). BioSTAR West was founded in 2005 to generate research and development expertise in biopolymer processing and polymer interactions with mammalian cells and bacteria. This research led to chemical modifications of a natural biopolymer and examination of the molecular interactions of these derivatives with tissue and bacterial pathogens. Synedgen is managed by an experienced team of scientists and business executives with strengths in innovation, synthetic and analytical chemistry, microbiological research, clinical research, regulatory process, product development, corporate partnering, FDA approvals, and successful non-dilutive fundraising.

Kyoto Biopharma, Inc., a subsidiary of Ace Hightech Co., Ltd., is a company headquartered in Kyoto, Japan, that engages pharmaceuticals preparation and distribution. Ace Hightech Co., Ltd. acquired Kyoto Biopharma, Inc. on November 12, 2013 for $13.99 million.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

Shenzhen Yiminuo Pharmaceutical Technology Co., Ltd., established on 2015-07-27, Business scope includes general business items:,The licensing program is:Antibody and vaccine development,Prevention and treatment of drug-resistant Staphylococcus aureus in humans with non-antibiotics(Staphylococcus aureus)disease caused by infection,And on this basis, engage in the research and development of other related pharmaceutical products(Certificate operation involving license,Except for national prohibitions and restrictions;Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

AKO Kasei Co. Ltd. is a Japanese private company that manufactures bottled sea water, chemicals and salt.